Abstract
Bortezomib suppressing NF-κB activity is an effective therapy for patients with myeloma or lymphoma. However, this drug can cause adverse effects, neutropenia, and recurrent infections of herpes viruses. Among herpes viruses, HSV-1 can reactivate to induce mortality. The important issues regarding how bortezomib diminishes neutrophils, whether bortezomib can induce HSV-1 reactivation, and how bortezomib exacerbates HSV-1 infection, need investigation. Using the murine model, we found that bortezomib induced HSV-1 reactivation. Bortezomib diminished neutrophil numbers in organs of uninfected and HSV-1-infected mice and turned a nonlethal infection to lethal with elevated tissue viral loads. In vitro results showed that bortezomib and HSV-1 collaborated to enhance the death and apoptosis of mouse neutrophils. The leukocyte deficiency induced by chemotherapies is generally believed to be the cause for aggravating virus infections. Here we show the potential of pathogen to exacerbate chemotherapy-induced leukocyte deficiency.
| Original language | English |
|---|---|
| Pages (from-to) | 105-112 |
| Number of pages | 8 |
| Journal | Journal of Leukocyte Biology |
| Volume | 107 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2020 Jan 1 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Immunology and Allergy
- Immunology
- Cell Biology
Cite this
}
Bortezomib induces HSV-1 lethality in mice with neutrophil deficiency. / Yao, Hui Wen; Wang, Li Chiu; Tsai, Hsien Yang; Fang, Yi Hsuan; Zheng, Chunfu; Chen, Shun Hua; Hsu, Sheng Min.
In: Journal of Leukocyte Biology, Vol. 107, No. 1, 01.01.2020, p. 105-112.Research output: Contribution to journal › Article
TY - JOUR
T1 - Bortezomib induces HSV-1 lethality in mice with neutrophil deficiency
AU - Yao, Hui Wen
AU - Wang, Li Chiu
AU - Tsai, Hsien Yang
AU - Fang, Yi Hsuan
AU - Zheng, Chunfu
AU - Chen, Shun Hua
AU - Hsu, Sheng Min
PY - 2020/1/1
Y1 - 2020/1/1
N2 - Bortezomib suppressing NF-κB activity is an effective therapy for patients with myeloma or lymphoma. However, this drug can cause adverse effects, neutropenia, and recurrent infections of herpes viruses. Among herpes viruses, HSV-1 can reactivate to induce mortality. The important issues regarding how bortezomib diminishes neutrophils, whether bortezomib can induce HSV-1 reactivation, and how bortezomib exacerbates HSV-1 infection, need investigation. Using the murine model, we found that bortezomib induced HSV-1 reactivation. Bortezomib diminished neutrophil numbers in organs of uninfected and HSV-1-infected mice and turned a nonlethal infection to lethal with elevated tissue viral loads. In vitro results showed that bortezomib and HSV-1 collaborated to enhance the death and apoptosis of mouse neutrophils. The leukocyte deficiency induced by chemotherapies is generally believed to be the cause for aggravating virus infections. Here we show the potential of pathogen to exacerbate chemotherapy-induced leukocyte deficiency.
AB - Bortezomib suppressing NF-κB activity is an effective therapy for patients with myeloma or lymphoma. However, this drug can cause adverse effects, neutropenia, and recurrent infections of herpes viruses. Among herpes viruses, HSV-1 can reactivate to induce mortality. The important issues regarding how bortezomib diminishes neutrophils, whether bortezomib can induce HSV-1 reactivation, and how bortezomib exacerbates HSV-1 infection, need investigation. Using the murine model, we found that bortezomib induced HSV-1 reactivation. Bortezomib diminished neutrophil numbers in organs of uninfected and HSV-1-infected mice and turned a nonlethal infection to lethal with elevated tissue viral loads. In vitro results showed that bortezomib and HSV-1 collaborated to enhance the death and apoptosis of mouse neutrophils. The leukocyte deficiency induced by chemotherapies is generally believed to be the cause for aggravating virus infections. Here we show the potential of pathogen to exacerbate chemotherapy-induced leukocyte deficiency.
UR - http://www.scopus.com/inward/record.url?scp=85075385177&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85075385177&partnerID=8YFLogxK
U2 - 10.1002/JLB.4AB1019-495R
DO - 10.1002/JLB.4AB1019-495R
M3 - Article
C2 - 31729784
AN - SCOPUS:85075385177
VL - 107
SP - 105
EP - 112
JO - Journal of Leukocyte Biology
JF - Journal of Leukocyte Biology
SN - 0741-5400
IS - 1
ER -